Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France on volume and cost of drug deliveries, assessed with administrative databases.
Fiche publication
Date publication
septembre 2020
Journal
Seminars in arthritis and rheumatism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis
Tous les auteurs :
Mari K, Rannou F, Guillemin F, Elegbede M, Gueyffier F, Badot G, Mistretta F
Lien Pubmed
Résumé
As one of the leading causes of disability in adults worldwide, its toll on patients and its economic burden for payers are substantial. The issue of change in OA management with the evolution of reimbursement schemes needs to be addressed.
Mots clés
Cost, Hospitalization, NSAID, Osteoarthritis, Reimbursement, SYSADOA
Référence
Semin Arthritis Rheum. 2020 Sep 23;50(6):1307-1313